145 related articles for article (PubMed ID: 29463149)
1. Transition from Hybrid Capture 2 to Cobas 4800 in Hpv detection: sensitivity and specificity for Cin2+ in two time periods.
Bottari F; Boveri S; Iacobone AD; Gulmini C; Igidbashian S; Cassatella MC; Landoni F; Sandri MT
Infect Dis (Lond); 2018 Jul; 50(7):554-559. PubMed ID: 29463149
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
Oštrbenk A; Xu L; Arbyn M; Poljak M
J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30209184
[TBL] [Abstract][Full Text] [Related]
3. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study.
Rao A; Sandri MT; Sideri M; Young S; Sharma A; Behrens C
J Clin Virol; 2013 Sep; 58(1):161-7. PubMed ID: 23895930
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of three commercial systems for detection of high-risk human papillomavirus in cervical and vaginal ThinPrep PreservCyt samples and correlation with biopsy results.
Binnicker MJ; Pritt BS; Duresko BJ; Espy MJ; Grys TE; Zarka MA; Kerr SE; Henry MR
J Clin Microbiol; 2014 Oct; 52(10):3763-8. PubMed ID: 25122861
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA.
Park Y; Lee E; Choi J; Jeong S; Kim HS
J Clin Microbiol; 2012 Jul; 50(7):2359-65. PubMed ID: 22518863
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the PANArray HPV Genotyping Chip Test with the Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of HPV in ASCUS Women.
Ki EY; Lee YK; Lee A; Park JS
Yonsei Med J; 2018 Jul; 59(5):662-668. PubMed ID: 29869464
[TBL] [Abstract][Full Text] [Related]
7. Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities.
Cornall AM; Poljak M; Garland SM; Phillips S; Tan JH; Machalek DA; Quinn MA; Tabrizi SN
Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):545-551. PubMed ID: 27822653
[TBL] [Abstract][Full Text] [Related]
8. Anyplex II HPV test in detection and follow-up after surgical treatment of CIN2+ lesions.
Bottari F; Iacobone AD; Radice D; Preti EP; Preti M; Franchi D; Piana AF; Sandri MT; Passerini R
J Med Virol; 2021 Nov; 93(11):6340-6346. PubMed ID: 33565607
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the analytical and clinical performance of five tests for the detection of human papillomavirus genital infection.
Del Pino M; Alonso I; Rodriguez-Trujillo A; Bernal S; Geraets D; Guimerà N; Torne A; Ordi J
J Virol Methods; 2017 Oct; 248():238-243. PubMed ID: 28739302
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology.
Rebolj M; Lynge E; Ejegod D; Preisler S; Rygaard C; Bonde J
Gynecol Oncol; 2014 Dec; 135(3):474-80. PubMed ID: 25449563
[TBL] [Abstract][Full Text] [Related]
11. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.
Dalstein V; Merlin S; Bali C; Saunier M; Dachez R; Ronsin C
J Virol Methods; 2009 Mar; 156(1-2):77-83. PubMed ID: 19041893
[TBL] [Abstract][Full Text] [Related]
12. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.
Ejegod DM; Hansen M; Christiansen IK; Pedersen H; Quint W; Xu L; Arbyn M; Bonde J
J Clin Virol; 2020 Jul; 128():104336. PubMed ID: 32446166
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
Xu L; Oštrbenk A; Poljak M; Arbyn M
J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a Novel Single-Tube Method for Extended Genotyping of Human Papillomavirus.
Bhatia R; Serrano I; Wennington H; Graham C; Cubie H; Boland E; Fu G; Cuschieri K
J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29237790
[TBL] [Abstract][Full Text] [Related]
16. Comparison of INNO-LiPA genotyping extra and hybrid capture 2 assays for detection of carcinogenic human papillomavirus genotypes.
Barzon L; Militello V; Pagni S; Palù G
J Clin Virol; 2012 Nov; 55(3):256-61. PubMed ID: 22877561
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the digene hybrid capture 2 and Roche cobas 4800 HPV tests for detection of CIN2+ in a referral population in Japan.
Sasagawa T; Maehama T; Osaka Y; Sakamoto J; Shibata T; Fujita S; Takakura M; Takagi H
J Med Virol; 2018 May; 90(5):972-980. PubMed ID: 29315626
[TBL] [Abstract][Full Text] [Related]
18. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
19. Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.
Dong L; Feng RM; Zhang L; Xu XQ; Zhao XL; Wang MZ; Qiao YL; Zhao FH
J Gynecol Oncol; 2017 Sep; 28(5):e66. PubMed ID: 28657227
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
